J-Matthias Graf von der Schulenburg

List of Publications by Year
in descending order

20 papers	859 citations	687363 13 h-index	610901 24 g-index
27 all docs	27 docs citations	27 times ranked	1406 citing authors

#	Article	IF	Citations
1	Evaluation of two family-based intervention programs for children affected by rare disease and their families â€“ research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design. BMC Family Practice, 2020, 21, 239.	2.9	18
2	Use and importance of different information sources among patients with rare diseases and their relatives over time: a qualitative study. BMC Public Health, 2020, 20, 860.	2.9	13
3	Costs of isocyanate-related occupational diseases: A systematic review. Journal of Occupational and Environmental Hygiene, 2019, 16, 446-466.	1.0	4
4	Patient-reported data informing early benefit assessment of rare diseases in Germany: A systematic review. Health Economics Review, 2019, 9, 34.	2.0	6
5	Authorsâ€™ reply to Gandjour: â€œModeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germanyâ€. European Journal of Health Economics, 2018, 19, 473-481.	2.8	1
6	German Value Set for the EQ-5D-5L. Pharmacoeconomics, 2018, 36, 663-674.	3.3	316
7	Telephone health services in the field of rare diseases: a qualitative interview study examining the needs of patients, relatives, and health care professionals in Germany. BMC Health Services Research, 2018, 18, 99.	2.2	12
8	Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study. JMIR Research Protocols, 2018, 7, e112.	1.0	1
9	Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. European Journal of Health Economics, 2017, 18, 273-292.	2.8	18
10	Cost analysis of whole genome sequencing in German clinical practice. European Journal of Health Economics, 2017, 18, 623-633.	2.8	27
11	Valuation of the EQ-5D-5L with composite time trade-off for the German population â€“ an exploratory study. Health and Quality of Life Outcomes, 2017, 15, 39.	2.4	16
12	Therapy preferences of patients with lung and colon cancer: a discrete choice experiment. Patient Preference and Adherence, 2017, Volume 11, 1647-1656.	1.8	18
13	Comparison of different approaches applied in Analytic Hierarchy Process â€“ an example of information needs of patients with rare diseases. BMC Medical Informatics and Decision Making, 2016, 16, 117.	3.0	25
14	Benefit assessment in Germany: implications for price discounts. Health Economics Review, 2016, 6, 33.	2.0	16
15	Applying the Analytic Hierarchy Process in healthcare research: A systematic literature review and evaluation of reporting. BMC Medical Informatics and Decision Making, 2015, 15, 112.	3.0	124
16	Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis -. Health Economics Review, 2015, 5, 40.	2.0	19
17	The Role of decision-analytic modelling in German health technology assessments. Health Economics Review, 2015, 5, 7.	2.0	1
18	EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Nonâ€“Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1254-1261.	2.5	38

#	Article	IF	Citations
19	Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. European Journal of Health Economics, 2015, 16, 113-118.	2.8	36
20	German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. Value in Health, 2008, 11, 539-544.	0.3	138